ArticleCureus2026
Synchronous Clear Cell and Papillary Renal Cell Carcinoma Collision Tumor Confirmed by Component-Specific Next-Generation Sequencing: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synchronous clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) within the same kidney are uncommon, and distinguishing a true collision tumor from a composite neoplasm with shared clonal origin requires molecular confirmation. We report an 83-year-old woman who underwent radical nephrectomy for an incidentally detected left renal mass. Pathologic examination revealed two well-demarcated adjacent tumors (3.3 cm and 3.2 cm) with characteristic morphologic and immunophenotypic features of ccRCC and pRCC, both staged pT1a. Separate next-generation sequencing analyses demonstrated completely distinct molecular profiles: the pRCC harbored RHEB p.Y35C and TERT promoter mutations with TMB-High status, whereas the ccRCC contained truncating alterations in PBRM1, ARID1A, and TGFBR1. No shared somatic mutations were identified, confirming independent clonal origins and establishing this as a true collision tumor. This case illustrates the value of per-component molecular profiling for histologically discordant renal tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.